Quetiapine fumarate, marketed under the brand name Seroquel, is an atypical antipsychotic medication widely used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder. The market for quetiapine fumarate is significant and continues to grow driven by several key factors.
The quetiapine fumarate market is segmented by the healthcare provider and patients. The healthcare provider is the contact point for analyzing the demand and exploring alternative therapies. They will assess the available alternatives and develop therapy options for the market focus.
The quetiapine fumarate market is segmented based on therapeutic applications, including:inhibiting neuroplasticity, regulating sodium levels in the brain, and managing conditions such as hypertension
The market for quetiapine fumarate is primarily driven by several factors: demand from medical devices, device segment
cost effectiveness, device segment accessibility, and pharmaceutical segment and growing indicationsThe cost effectiveness, accessibility, and cost savings of quetiapine fumarate are significant drivers for the market. Market dynamics
The increasing demand from medical devices, device, and access groups is a significant driver for the quetiapine fumarate market. The cost effectiveness, accessibility, and accessibility to generic alternatives is expected to drive market growth in these areas.
Current Market TrendsThe company has announced that it will make an agreement with AstraZeneca over a license with the U. S. government to market a generic version of its blockbuster antipsychotic drug Seroquel (quetiapine fumarate), to be sold at a price of $30 to $70.
The deal could save the company $8 billion each year, a price tag that is expected to exceed $10 billion, AstraZeneca said.
Seroquel is the world's first antipsychotic drug with a safety record of more than 6,000 suicides in the United States, including a suicide attempt and more than 2,000 deaths in the years 2000 to 2010. The generic is also one of only a handful of other new antipsychotic drugs in the U. to have U. sales of more than $3 billion each.
AstraZeneca also agreed to license its Seroquel generic to a US government agency, the Food and Drug Administration (FDA).
AstraZeneca is now facing a federal judge in New York that will decide if the company can get the license for Seroquel from the FDA.
AstraZeneca's Seroquel was developed as an antipsychotic drug, and was approved to treat schizophrenia in schizophrenia-related disorders in 1996. But the drug was later approved to treat the disorder for which the drug was marketed. The company has filed suit with the FDA for the agency to approve a generic version of the drug, which it hopes will be sold at a price of $30 to $70 a month.
The judge ruled in AstraZeneca's favor on Wednesday against the company's proposed license.
"The company is well aware of the fact that it is under a cloud of uncertainty as to whether it will be able to obtain the license from the FDA," said Dr. Steven Nissen, medical affairs chief at the Center for Drug Evaluation and Research in New York City.
Nissen said the company is seeking to appeal the ruling.
Seroquel is the world's first drug to be approved to treat schizophrenia and is expected to be marketed at a price of $30 to $70 a month.
For the company to get the FDA's approval, AstraZeneca must first submit a certification from the FDA and then sell the drug. AstraZeneca must then demonstrate that the company has complied with all applicable regulations.
AstraZeneca will be required to submit the certification and other required documents to the FDA to market the drug.
The company also must submit a plan to the FDA to achieve the agreement, AstraZeneca said. The company will also need to meet the costs and benefits of the plan.
Seroquel will be sold at a retail price of $30 to $70 a month.
Copyright © 2025 NPR. All rights reserved. Do not share or use this material for commercial gain.lawmakers in several countries around the world have sued the drug industry to get the generic drug approval needed to treat the disorder.
The companies, along with several smaller companies, have filed lawsuits against the U. government to get the drug approval needed to treat the disorder.
The cases have been before courts in more than 100 other countries.
The lawsuits have been consolidated in federal courts in several countries to make sure that all the defendants get the same lawsuit.
Some of the defendants in the lawsuits include AstraZeneca, Eli Lilly and Novartis Pharmaceuticals, Pfizer, Merck & Co., GlaxoSmithKline and Teva Pharmaceutical Industries.
The lawsuit was started by former employees of the company who were sued by a judge on behalf of a woman who died after taking Seroquel in a heart attack.
AstraZeneca was sued in federal court over Seroquel's patent for the drug from the U. government in 2000.
The lawsuit claimed that AstraZeneca knew or should have known about the risks of Seroquel in its blockbuster antipsychotic drug, Seroquel.
The suit also alleged that AstraZeneca failed to take the required steps to prevent the suicide of a patient in a heart attack when Seroquel was first made available.
AstraZeneca also has agreed to buy the remaining generic rights of its blockbuster antipsychotic drug, Zyprexa, from GlaxoSmithKline after it was ordered to do so by a judge.
The settlement also provides that AstraZeneca will pay $520 million to resolve lawsuits filed by individuals who developed heart disease as a result of taking the drug.
[]
There are two main differences between Seroquel and Zyprexa:
The primary difference between Seroquel and Zyprexa is the use of quetiapine. Quetiapine is an anti-psychotic that helps to lower the level of dopamine in the brain. It is also available in a tablet form, making it easier to take the medication.
Seroquel can be taken either with or without food. However, it's important to take the medication at the same time each day to maintain a consistent level of dopamine in the brain. Seroquel can help to relieve symptoms of depression and anxiety and can be taken during the day and at night. Seroquel can also help to manage weight gain and reduce weight associated with obesity. Zyprexa can be used in conjunction with a reduced-calorie diet and exercise.
The main difference between Seroquel and Zyprexa is the availability of quetiapine. Quetiapine is an antipsychotic medication that can help to balance the levels of dopamine and serotonin in the brain. Seroquel can also help to reduce weight gain and increase weight loss associated with obesity.
The use of quetiapine can help to improve mood and feelings related to depression. It can help to manage feelings of sadness and hopelessness. It can also help to lower the amount of cortisol in the body. This can help to increase the level of a stress hormone called cortisol. Seroquel can help to decrease the amount of adrenaline in the body. This can help to increase the amount of cortisol in the body and this can help to increase appetite and reduce stress.
Common side effects of Seroquel include:
Seroquel may cause serious side effects, including:
Zyprexa may cause serious side effects, including:
If you experience any of the following side effects or have any concerns about your health, it's important to discuss them with your doctor or pharmacist:
It's important to note that Seroquel should be used regularly to achieve the best results, and that it is not recommended to adjust your dose or frequency beyond that prescribed by your doctor. The medication may need to be stopped and the improvement in symptoms reported in some cases may be temporary. It's important to have an accurate dose and to monitor your weight regularly. If you have any questions or concerns about your treatment, contact your doctor or pharmacist.
Zyprexa should be used with extreme caution, as it can cause serious side effects.
Published:16:09 BST, 18 November 2011
Seroquel XR, the new anti-psychotic drug for schizophrenia, has been withdrawn after being reported to have been linked to severe mood changes and suicidal behaviour.
AstraZeneca’s Seroquel XR is the second schizophrenia drug to be withdrawn from the market after being linked to suicidal behaviour in patients with schizophrenia.
The drug is a combination of quetiapine and aripiprazole, a second-generation antipsychotic that was introduced in 2010.
The company’s Seroquel has been prescribed to more than 12,000 patients for schizophrenia, according to the Medicines and Healthcare products Regulatory Agency (MHRA), and was found to be in the ‘at risk’ category.
Seroquel, which was developed by AstraZeneca, was approved by the MHRA in November 2010 to treat schizophrenia, and was available in the UK since that time.
It was introduced to the UK in September 2010, with its first UK launch in September.
AstraZeneca’s Seroquel XR is the second schizophrenia drug to be withdrawn from the market after being reported to have been linked to severe mood changes and suicidal behaviour.
The drug, which is sold under the brand name Seroquel, is the brand-name for the quetiapine and aripiprazole (aripiprazole) in quetiapine, which is the same drug as Seroquel.
The drug is also being withdrawn from the market due to its potential side-effects.
The Seroquel XR was developed by AstraZeneca and marketed as an anti-psychotic drug in the US by AstraZeneca Pharmaceuticals.
AstraZeneca is the second company to lose its patent on Seroquel, after its US patent expired in July 2010.
In 2011, AstraZeneca acquired the rights to its Seroquel drug from AstraZeneca Pharmaceuticals. This agreement allowed AstraZeneca to expand its product portfolio in the US to include other anti-psychotic drugs.
AstraZeneca’s Seroquel XR was approved by the MHRA in November 2010 to treat schizophrenia, and was available in the UK since that time.
AstraZeneca’s Seroquel XR was developed by AstraZeneca and marketed as an anti-psychotic drug in the US by AstraZeneca Pharmaceuticals.
In December 2011, AstraZeneca acquired the rights to Seroquel XR from AstraZeneca Pharmaceuticals.
In July 2012, AstraZeneca acquired the rights to Seroquel XR from AstraZeneca Pharmaceuticals.
The company is the second company to lose its patent on Seroquel, after its US patent expired in July 2010.
Stade de France Pharmacy